4.78

3.82% -0.19

After Hours: 4.78

Bioage Labs Inc (BIOA)

Overview News Price History Discussions Forecast

Bioage Labs Inc stock is traded at $4.78, with a volume of 213.60K. It is down -3.82% in the last 24 hours and down -15.55% over the past month. Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.

Previous Close:

$4.97

Open:

$5.05

24h Volume:

213.60K

Relative Volume:

0.31

Market Cap:

$171.36M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-9.81%

1M Performance:

-15.55%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$4.75

$5.05

1-Week Range:

$4.75

$5.45

52-Week Range:

$3.85

$26.62

Bioage Labs Inc Stock (BIOA) Company Profile

Name

Bioage Labs Inc

Sector

Healthcare (1174)

Industry

Drug Manufacturers - Specialty & Generic (1)

Phone

510-806-1445

Address

1445A SOUTH 50TH STREET, RICHMOND

Employee

Twitter

Next Earnings Date

Latest SEC Filings

BIOA's Discussions on Twitter

Compare BIOA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BIOA Bioage Labs Inc	4.78	171.36M	0	0	0	0.00
ZTS Zoetis Inc	172.71	77.92B	9.15B	2.43B	2.31B	5.32
TAK Takeda Pharmaceutical Co Adr	13.70	43.43B	30.27B	1.93B	3.45B	0.6044
HLN Haleon Plc Adr	9.57	43.27B	14.26B	1.55B	0	0.3383
TEVA Teva Pharmaceutical Industries Ltd Adr	17.84	20.21B	16.77B	-959.00M	1.37B	-0.85
NBIX Neurocrine Biosciences Inc	153.29	15.52B	2.24B	385.90M	440.10M	3.73

Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-10-24	Downgrade	Morgan Stanley	Overweight → Underweight
Dec-09-24	Downgrade	Citigroup	Buy → Neutral
Dec-09-24	Downgrade	Jefferies	Buy → Hold
Oct-21-24	Initiated	Citigroup	Buy
Oct-21-24	Initiated	Jefferies	Buy
Oct-21-24	Initiated	Morgan Stanley	Overweight

View All

Bioage Labs Inc Stock (BIOA) Latest News

05:45 AM

2025-01-30 | BioAge Labs, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your RightsBIOA | NDAQ:BIOA | Press Release - Stockhouse Publishing

05:45 AM

02:30 AM

2025-01-30 | Levi & Korsinsky Reminds BioAge Labs, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025BIOA | NDAQ:BIOA | Press Release - Stockhouse Publishing

02:30 AM

12:47 PM

Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights – BIOA - GlobeNewswire

12:47 PM

09:15 AM

2025-01-30 | Shareholders That Lost Money on BioAge Labs, Inc. (BIOA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More | NDAQ:BIOA | Press Release - Stockhouse Publishing

09:15 AM

05:45 AM

The Gross Law Firm Reminds BioAge Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025BIOA - PR Newswire

05:45 AM

Jan 29, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire

Jan 29, 2025

BioAge Labs (BIOA) Faces Securities Class Action On Behalf - GlobeNewswire

Jan 29, 2025

BioAge Labs (BIOA) Faces Securities Class Action On Behalf Of IPO Investors After Discontinuing Weight-Loss Drug Trial– Hagens Berman - GlobeNewswire Inc.

Jan 29, 2025

2025-01-29 | Levi & Korsinsky Reminds BioAge Labs, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025BIOA | NDAQ:BIOA | Press Release - Stockhouse Publishing

Jan 29, 2025

Class Action Filed Against BioAge Labs, Inc. (BIOA) Seeking Recovery for InvestorsContact Levi & Korsinsky - Stockhouse Publishing

Jan 29, 2025